Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults

Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults

Friday, December 9, 2022
Webinar -- 8:00 AM CT
https://www.clinicaloptions.com/ALLHEME2022Join1

Agenda

  • Welcome and Introduction
  • Applying Lessons and Experience in Pediatric Patients to the Treatment of AYA and Adult Patients With ALL Daniel J. DeAngelo, MD, PhD
  • Practical Considerations for Administration of Asparaginase-Based Therapy to Patients with ALL: Hypersensitivity or Intolerance or Inactivation? Kjeld Schmiegelow, MD
  • Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL Emily Curran, MD
  • Final Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‚ÄźFarber Cancer Institute
Boston, Massachusetts

Faculty
Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Faculty
Kjeld Schmiegelow, MD

Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with ALL.

Target Audience
This program is intended for physicians and other healthcare professionals who care for adolescent/young adult and adult patients with acute lymphoblastic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select, optimize, and apply asparaginase-containing regimens for adolescent/young adult and adult patients
  • Identify optimal methods of measuring and monitoring subclinical hypersensitivity or silent inactivation
  • Plan optimal approaches to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate into practice expert recommendations and insights from available data on reexposure of asparaginase treatments or use of recombinant asparaginase formulations
  • Discuss recent clinical evidence and current recommendations for optimizing the therapeutic regimens for adolescent/young adult patients with ALL with pediatric-inspired protocols

Accreditation

YOUR CONFIRMATION

Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults

On behalf of Clinical Care Options, LLC, we are pleased to confirm your registration for the upcoming event.

Date:        Friday, December 9, 2022
Time:        TBD
Location:  https://www.clinicaloptions.com/ALLHEME2022Join1

Agenda
Welcome and Introduction
Applying Lessons and Experience in Pediatric Patients to the Treatment of AYA and Adult Patients With ALL Daniel J. DeAngelo, MD, PhD
Practical Considerations for Administration of Asparaginase-Based Therapy to Patients with ALL: Hypersensitivity or Intolerance or Inactivation? Kjeld Schmiegelow, MD
Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL – Emily Curran, MD
Final Panel Discussion and Audience Question and Answer Session

Complete program information regarding faculty, agenda, and CME credit is available online at: events.clinicaloptions.com.

Questions? Please email customersupport@cealliance.com

                                                                            
Provided by Clinical Care Options, LLC.
Supported by an educational grant from Jazz Pharmaceuticals.
Copyright 2022 Clinical Care Options, LLC. All rights reserved.
Clinical Care Options, LLC 12001 Sunrise Valley Drive, Suite 300, Reston, VA 20191